September 26, 2016 1:17 AM ET

Healthcare Providers and Services

Company Overview of 21st Century Oncology Holdings, Inc.

Company Overview

21st Century Oncology Holdings, Inc., together with its subsidiaries, operates as a physician-led provider of integrated cancer care services. Its radiation treatment services include external beam therapies, such as conformal radiation therapy, intensity modulated radiation therapy, and stereotactic radiosurgery, as well as internal radiation therapies, such as high-dose and low-dose rate brachytherapies, and radiopharmaceutical therapy. The company’s radiation treatment services also comprise image guided radiation therapy, Gamma function testing, and respiratory gating. In addition, it offers support services in the areas of psychological and nutritional counseling, as well as transportat...

2270 Colonial Boulevard

Fort Myers, FL 33907

United States

Founded in 1983

5,188 Employees

Phone:

239-931-7254

Key Executives for 21st Century Oncology Holdings, Inc.

Chief Executive Officer, President, Director and Member of Capital Allocation Committee
Age: 58
Co-Founder, Executive Director, Member of Executive Committee and Member of Capital Allocation Committee
Age: 62
Chief Financial Officer
Age: 51
Chief Executive Officer of Medical Developers Cooperatief U.A. B.V., Chief Executive Officer of Vidt Centro Medico, President of Medical Developers Cooperatief U.A. B.V. and President of Vidt Centro Medico
Age: 56
Chief Medical Officer
Age: 46
Compensation as of Fiscal Year 2016.

21st Century Oncology Holdings, Inc. Key Developments

21st Century Oncology Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2016; Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016; Reports Impairment Loss for the Second Quarter Ended June 30, 2016

21st Century Oncology reported unaudited consolidated earnings results for the first quarter ended March 31, 2016. For the first quarter, the company reported total revenues of $270,298,000 compared to $275,633,000 a year ago. Income before income taxes and equity interest in net income of joint ventures were $4,528,000 compared to loss before income taxes and equity interest in net income of joint ventures of $12,499,000 a year ago. Net income attributable to company’s shareholder was $825,000 compared to net loss of $16,667,000 a year ago. Net cash used in operating activities were $36,688,000 compared to net cash provided by operating activities of $22,619,000 a year ago. Purchase of property and equipment was $12,259,000 compared to $12,199,000 a year ago. Acquisition of medical practices was $129,000 compared to $25,965,000 a year ago. Adjusted EBITDA was $38,994,000 compared to $42,283,000 a year ago. For the second quarter, the company reported total revenues of $258,383,000 compared to $278,213,000 a year ago. Loss before income taxes and equity interest in net income of joint ventures were $14,979,000 compared to $61,991,000 a year ago. Net loss attributable to company’s shareholder was $18,382,000 compared to net loss of $66,038,000 a year ago. Adjusted EBITDA was $33,350,000 compared to $46,241,000 a year ago. For the six months, the company reported total revenues of $528,681,000 compared to $553,846,000 a year ago. Loss before income taxes and equity interest in net income of joint ventures were $10,451,000 compared to $74,490,000 a year ago. Net loss attributable to company’s shareholder was $17,557,000 compared to net loss of $82,705,000 a year ago. Net cash used in operating activities were $35,457,000 compared to net cash provided by operating activities of $12,958,000 a year ago. Purchase of property and equipment was $20,195,000 compared to $25,753,000 a year ago. Acquisition of medical practices was $129,000 compared to $29,258,000 a year ago. Adjusted EBITDA was $72,343,000 compared to $88,524,000 a year ago. For the second quarter, the company reported impairment loss of $1,825,000.

21st Century Oncology Holdings, Inc. Announces Management Changes

21st Century Oncology Holdings, Inc. announced that its board of directors has appointed William (Bill) R. Spalding as president and CEO, effective immediately. He succeeds company founder Dr. Daniel Dosoretz, who will continue as a director and will transition to serving as a full-time senior physician with the company. Spalding, 58, was appointed a director of the company in May. He brings more than three decades of experience leading complex healthcare businesses and providing governance leadership. In conjunction with the CEO transition, the Board voted to reduce its size to six directors from eight. Dr. Howard Sheridan, director since 1988, and Erin Russell, director since February 2008, will transition from the Board.

21st Century Oncology Holdings, Inc., Q4 2015 Earnings Call, Sep 06, 2016

21st Century Oncology Holdings, Inc., Q4 2015 Earnings Call, Sep 06, 2016

Similar Private Companies By Industry

Company Name Region
@ Home Medical, Inc. United States
@home approach, llc United States
@Home Care United States
1011 E. Pecan Grove Road, LLC United States
1125 Sir Francis Drake Boulevard Operating Company, Llc United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact 21st Century Oncology Holdings, Inc., please visit www.rtsx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.